The drug is a product of AstraZeneca Group and is approved in 61 countries to date including the US, EU and Japan.
It is a combination of metformin and dapagliflozin, an inhibitor of sodium-glucose cotransporter 2, the company said in a statement.
Xigduo XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
"We believe this novel once-daily combination therapy of dapagliflozin and metformin can address an unmet medical need by offering a comprehensive and convenient treatment option for the Indian phenotype patient," AstraZeneca Pharma India Managing Director Gagan Singh Bedi said.
The combination of drug is backed by the XR (extended release) technology which provides 24-hour sugar control.
Eight in ten Indians display a characteristic feature of the Indian Phenotype (greater degree of central body obesity, higher insulin resistance and characteristic dyslipidemia) making them highly vulnerable to developing the nexus of type 2 diabetes, obesity and hypertension, the company said.
Xigduo XR is available in multiple dosage strengths of dapagliflozin and metformin HCI extended-release including 10/500 mg and 10/1000 mg.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)